134 related articles for article (PubMed ID: 37262421)
1. Magnetic-Manipulated NK Cell Proliferation and Activation Enhance Immunotherapy of Orthotopic Liver Cancer.
Jiang H; Fu H; Min T; Hu P; Shi J
J Am Chem Soc; 2023 Jun; 145(24):13147-13160. PubMed ID: 37262421
[TBL] [Abstract][Full Text] [Related]
2. Mild Magnetic Hyperthermia-Activated Innate Immunity for Liver Cancer Therapy.
Pan J; Xu Y; Wu Q; Hu P; Shi J
J Am Chem Soc; 2021 Jun; 143(21):8116-8128. PubMed ID: 33928777
[TBL] [Abstract][Full Text] [Related]
3. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
4. IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.
Easom NJW; Stegmann KA; Swadling L; Pallett LJ; Burton AR; Odera D; Schmidt N; Huang WC; Fusai G; Davidson B; Maini MK
Front Immunol; 2018; 9():1009. PubMed ID: 29867983
[TBL] [Abstract][Full Text] [Related]
5. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
6. Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy.
Lin X; Li F; Gu Q; Wang X; Zheng Y; Li J; Guan J; Yao C; Liu X
Acta Biomater; 2022 Jul; 146():406-420. PubMed ID: 35470078
[TBL] [Abstract][Full Text] [Related]
7. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F; Esmaeil N; Abbaspour M
Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
[TBL] [Abstract][Full Text] [Related]
8. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
[TBL] [Abstract][Full Text] [Related]
9. CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells.
Bashiri Dezfouli A; Yazdi M; Benmebarek MR; Schwab M; Michaelides S; Miccichè A; Geerts D; Stangl S; Klapproth S; Wagner E; Kobold S; Multhoff G
Front Immunol; 2022; 13():883694. PubMed ID: 35720311
[TBL] [Abstract][Full Text] [Related]
10. Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity.
Shin HY; Jang S; Woo HJ; Chung JH; Kim WH; Kim D; Kang M; Lim Y; Habib O; Lee J; Yang S; Lee DH; Kim MS
Theranostics; 2023; 13(5):1506-1519. PubMed ID: 37056568
[TBL] [Abstract][Full Text] [Related]
11. Magneto-Activation and Magnetic Resonance Imaging of Natural Killer Cells Labeled with Magnetic Nanocomplexes for the Treatment of Solid Tumors.
Sim T; Choi B; Kwon SW; Kim KS; Choi H; Ross A; Kim DH
ACS Nano; 2021 Aug; 15(8):12780-12793. PubMed ID: 34165964
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells.
Quatrini L; Vacca P; Tumino N; Besi F; Di Pace AL; Scordamaglia F; Martini S; Munari E; Mingari MC; Ugolini S; Moretta L
J Allergy Clin Immunol; 2021 Jan; 147(1):349-360. PubMed ID: 32417134
[TBL] [Abstract][Full Text] [Related]
13. Unlocking the power of immunotherapy: Combinatorial delivery of plasmid IL-15 and gemcitabine to synergistically remodeling the tumor microenvironment.
Liu J; Han Y; Zhao M; Wang L; Hu H; Chen D
Int J Pharm; 2024 Apr; 655():124027. PubMed ID: 38554742
[TBL] [Abstract][Full Text] [Related]
14. NK cell immunometabolism as target for liver cancer therapy.
Wang J; Liu X; Jin T; Cao Y; Tian Y; Xu F
Int Immunopharmacol; 2022 Nov; 112():109193. PubMed ID: 36087507
[TBL] [Abstract][Full Text] [Related]
15. Construction and Mechanism of IL-15-Based Coactivated Polymeric Micelles for NK Cell Immunotherapy.
Shao D; Bai T; Zhu B; Guo X; Dong K; Shi J; Huang Q; Kong J
Adv Healthc Mater; 2024 Feb; 13(4):e2302589. PubMed ID: 37897328
[TBL] [Abstract][Full Text] [Related]
16. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity.
Bernard PL; Delconte R; Pastor S; Laletin V; Costa Da Silva C; Goubard A; Josselin E; Castellano R; Krug A; Vernerey J; Devillier R; Olive D; Verhoeyen E; Vivier E; Huntington ND; Nunes J; Guittard G
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35589278
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
Choi JW; Lee ES; Kim SY; Park SI; Oh S; Kang JH; Ryu HA; Lee S
BMC Cancer; 2019 Aug; 19(1):817. PubMed ID: 31426763
[TBL] [Abstract][Full Text] [Related]
18.
Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
Front Immunol; 2019; 10():454. PubMed ID: 30967859
[TBL] [Abstract][Full Text] [Related]
19. iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.
Dong Y; Huang Y; Zhang Z; Chen A; Li L; Tian M; Shen J; Shao J
J Transl Med; 2023 Mar; 21(1):205. PubMed ID: 36932395
[TBL] [Abstract][Full Text] [Related]
20. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
